Issue link: https://www.e-digitaleditions.com/i/1254974
Recent news items on research and development, and progress in the treatment of respiratory diseases, such as asthma, COPD and tuberculosis as well as news about other topics including COVID-19. Inhalation June 2020 25 potent stimulation of mucosal and cellular immune responses in addi- tion to a strong serum antibody response. It is hoped that when combined with the intranasal route of administration, this may allow for efficient and inexpensive distri- bution of the vaccine. Neurimmune and Ethris to collaborate on inhaled COVID-19 therapy Z U R I C H , S W I T Z E R L A N D AND MUNICH, GERMANY— Ne u r i m m u n e AG a n d Et h r i s has experience in development of intranasal vaccines candidates for respiratory pathogens, including NasoVAX, a seasonal and pan- demic influenza vaccine candi- date, and NasoShield, a vaccine candidate for anthrax. By utiliz- ing the Altimmune's proprietary intranasal vaccine technology, it is expected that AdCOVID has the potential to activate multiple arms of the immune system. e capa- bility was shown in a recent Phase II study with NasoVAX, which is based on the same technology platform. at study also showed Industry news continued from page 8 dose inhaler (pMDI) formula- tion of ensifentrine in a Phase II clinical trial in patients with mod- erate to severe chronic obstruc- tive pulmonary disease (COPD). Results from the single dose part of the study (Part A) demonstrated a statistically significant and clin- ically meaningful increase in lung function as measured by forced expiratory volume in one second (FEV₁) compared to placebo. e positive findings support initiation of a second, multiple dose, study (Part B), which will evaluate the pMDI formulation over seven days of twice-daily treatment. Although postponed due to COVID-19, an updated timeline for the Part B study will be announced at a later date. e company explained that, with these results and those observed in previous Phase II clin- ical trials, ensifentrine has demon- strated statistically significant and clinically meaningful improve- ments in lung function in COPD patients when delivered by neb- ulizer, dry powder inhalers (DPI) and pMDI. respIratory medIcIne news Altimmune and UAB to develop intranasal vaccine for COVID-19 G A I T H E R S B U RG , M A RY- LAND—Globe Newswire reported that Altimmune, Inc. has created AdCOVID, a single dose, intra- nasal vaccine candidate designed to protect against COVID-19, the disease caused by the SARS- CoV-2 virus. The company will collaborate with the University of Alabama at Birmingham (UAB) on preclinical animal studies and characterization of the vaccine immunogenicity. Their goal is enabling a Phase I clinical trial in third quarter of 2020. Founded in 1997 through a technology license from UAB, Altimmune ONE CUSTOMER, ONE CAPSULE Capsules are the very essence of Qualicaps ® As a company dedicated to capsules we have a unique perspective on how to contribute to health. Qualicaps ® delivers pharmaceutical-grade capsules together with a comprehensive service along the drug product life cycle through our global team of commercial, scientific and technical services. Quali-V ® -I capsules for inhaled drug delivery. Quali-V ® -I Extra Dry, when a minimum moisture content level is required Strict Microbiological Control Reduced Powder Adhesion Superior Puncturing Properties Lower moisture content (2.0 - 3.5%) Better Aerosolization Inner Surface Control Quali-V-I + Extra-Dry_Inhalation Magazine_116x190mm.indd 1 12/2/20 16:14